Works matching IS 20953941 AND DT 2023 AND VI 20 AND IP 5
Results: 6
Identification of the E2F1-RAD51AP1 axis as a key factor in MGMT-methylated GBM TMZ resistance.
- Published in:
- Cancer Biology & Medicine, 2023, v. 20, n. 5, p. 385, doi. 10.20892/j.issn.2095-3941.2023.0011
- By:
- Publication type:
- Article
Recent progress in targeting the sialylated glycan-SIGLEC axis in cancer immunotherapy.
- Published in:
- Cancer Biology & Medicine, 2023, v. 20, n. 5, p. 369, doi. 10.20892/j.issn.2095-3941.2023.0046
- By:
- Publication type:
- Article
Development of glioblastoma organoids and their applications in personalized therapy.
- Published in:
- Cancer Biology & Medicine, 2023, v. 20, n. 5, p. 353, doi. 10.20892/j.issn.2095-3941.2023.0061
- By:
- Publication type:
- Article
Expert opinion on translational research for advanced glioblastoma treatment.
- Published in:
- Cancer Biology & Medicine, 2023, v. 20, n. 5, p. 344, doi. 10.20892/j.issn.2095-3941.2023.0012
- By:
- Publication type:
- Article
Nanomedicine-based combination therapies for overcoming temozolomide resistance in glioblastomas.
- Published in:
- Cancer Biology & Medicine, 2023, v. 20, n. 5, p. 325, doi. 10.20892/j.issn.2095-3941.2022.0761
- By:
- Publication type:
- Article
Evolution-driven crosstalk between glioblastoma and the tumor microenvironment.
- Published in:
- Cancer Biology & Medicine, 2023, v. 20, n. 5, p. 319, doi. 10.20892/j.issn.2095-3941.2022.0771
- By:
- Publication type:
- Article